Monday, January 16, 2012

Roche Faces First Trial of Claims Over Raptiva Infections - Businessweek

Jan. 13 (Bloomberg) -- Roche Holding AG’s Genentech Inc. is facing the first trial of patients’ claims that its withdrawn Raptiva psoriasis drug spawned fatal infections in some users.

Officials of Genentech, a unit of Basel, Switzerland-based drugmaker Roche, are readying for a Jan. 30 jury trial in state court in California over allegations that Raptiva caused Stephen Johnson’s death. The 46-year-old Louisiana businessman took the drug to treat a skin condition. Genentech withdrew the medication from the market almost three years ago after it was linked to fatal brain infections.

“Psoriasis isn’t life-threatening and his wasn’t even that horrible,” Mark Lanier, a lawyer for Johnson’s family, said in an interview. “This drug was never about the patients. This drug was about the money.”

Posted via email from Jack's posterous

No comments: